Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843417 | 0.86 | ALDH1A1 (0.58) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL13545621 | 0.84 | GAA (0.69) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL22326350 | 0.82 | GAA (0.88) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL17650674 | 0.80 | GAA (0.64) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL13108193 | 0.78 | GAA (0.62) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL6570943 | 0.78 | GAA (0.74) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL2081294 | 0.78 | GAA (0.62) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL7475276 | 0.78 | GAA (0.62) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL1715729 | 0.78 | ALDH1A1 (1.00) | ALDH1A1GAAKMT2ACYP1A2MAPT | |
| SCHEMBL30767916 | 0.78 | ALDH1A1 (1.00) | ALDH1A1GAAKMT2ACYP1A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931723-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND -LACTAMASE INHIBITORS | Fedora Pharmaceuticals Inc. (CA) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014091268-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS | NAEJA PHARMACEUTICAL INC. (CA) | 2014-06-19 | — | — | WO | disclosed |
| CN-1863813-B | Novel tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA INC | 2011-03-30 | — | — | CN | disclosed |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-12-09 | — | — | US | disclosed |
| EP-1660511-B1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA SCIENT MANAGEMENT (AU) | 2010-11-03 | — | — | EP | disclosed |
| US-7713941-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-05-11 | — | — | US | disclosed |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2008-08-21 | — | — | US | disclosed |
| US-7268119-B2 | Tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-09-11 | — | — | US | disclosed |
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| CN-1863813-A | Novel tricyclic nucleosides or nucleotides as therapeutic agents | BIOTA INC (AU) | 2006-11-15 | — | — | CN | disclosed |
| EP-1660511-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | Biota, Inc. (AU) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021568-A2 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | BIOTA, INC. (AU) | 2005-03-10 | — | — | WO | disclosed |
| US-6762169-B1 | IMPROVED TRANSMEMBRANE DELIVERY OF NUCLEOSIDES CONJUGATED TO AN ARYLPROPIONIC ACID LIGAND (IBUPROFEN) WHICH HAS AFFINITY FOR PLASMA PROTEIN ALBUMIN; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. | 2004-07-13 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135363-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | ALDH1A1 3378/4885GAA 827/4885KMT2A 2793/4885 |
| US-20080200423-A1 | Novel Tricyclic Nucleosides or Nucleotides as Therapeutic Agents | NME1, NME2, NTPCR | ALDH1A1 4126/4885GAA 537/4885KMT2A 3054/4885 |
| US-20100311684-A1 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS | NTPCR, NME1, NME2 | ALDH1A1 3378/4885GAA 827/4885KMT2A 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.